Novel Immunomodulation and Facilitation of “Suppression Proof” CAR NK cell against Ewing sarcoma
新型免疫调节和促进“抑制证明”CAR NK 细胞对抗尤文肉瘤
基本信息
- 批准号:10834579
- 负责人:
- 金额:$ 25.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive ImmunotherapyAdoptive TransferAdultAntigensBindingBiological ProductsCancer BurdenCancer ModelCase StudyCell surfaceCellsChildhoodChildhood Solid NeoplasmClinicalClinical TrialsCombination immunotherapyComplementCytometryDataData SetDevelopmentDrug ModulationEffectivenessEwings sarcomaFundingFutureGenomic approachGenomicsGoalsHomingHybridsImmuneImmune responseImmunologic AdjuvantsImmunologic MonitoringImmunotherapyInflammatoryInnate Immune ResponseInterruptionKnowledgeMacrophageMalignant Childhood NeoplasmMalignant NeoplasmsMediatingMinnesotaModalityMutationMyeloid-derived suppressor cellsNatural ImmunityNatural Killer CellsNew YorkNormal CellOhioOncolytic virusesPatientsPediatric HospitalsPhysiciansPre-Clinical ModelProteinsRegimenResearch PersonnelResistanceResource SharingSTAT3 geneScientistSignal TransductionSiteSolid NeoplasmSourceT cell responseTechnologyTestingTherapeuticTractionTransforming Growth Factor betaTumor ImmunityUniversitiesVirotherapyVirusVirus Diseasesadaptive immunityanti-tumor immune responsecancer cellcancer immunotherapeuticscancer immunotherapychemokinechemoradiationchimeric antigen receptorchimeric antigen receptor T cellscombinatorialconventional therapycytokinedata integrationeffective therapyembryo/fetus antigenexperienceimmune cell checkpointsimmunogenicityimmunoregulationimmunotherapy clinical trialsimprovedinnate immune mechanismsmedical schoolsneoantigensnoveloncolytic virotherapypharmacologicpre-clinicalrational designresistance mechanismresponsesmall moleculesuccesssynergismtraffickingtranscriptomicstranslational studytumortumor microenvironmenttumor-immune system interactions
项目摘要
Overall Center Abstract
This application describes the Pediatric Ohio-New York Cancer (Peds-ONC) Immunotherapy Center, created in
response to the RFA as a second nidus for the Pediatric Immunotherapy Discovery and Development
Consortium (PI-DDN). To complement the funded U54 (Maris and Mackall, MPI) of the PI-DDN that largely
seeks to harness adaptive immunity to further develop CAR-T cells against newly identified antigens, we propose
to harness innate immunity to target pediatric cancers, to circumvent resistance to conventional therapy, and to
further enable adaptive/hybrid immune approaches.
Our aims are to (1) Identify and overcome barriers to utilizing NK and CAR-NK cells as cancer therapeutics, (2)
break tolerance to “self” cancer-associated proteins and (3) enhance immunotherapies by targeting suppressive
myeloid cells. We will accomplish our aims through four projects, based at two major sites based in Ohio
(Nationwide Children’s Hospital) and New York (New York Medical College) with subsites in Columbus (The
Ohio State University) and Minneapolis (Univeristy of Minnesota). In addition to an Administrative Shared
Resource (Core A, directed by Dr. Timothy Cripe and Associate Director Dr. Mitchell Cairo), the projects are
scientifically supported by a comprehensive Genomics & Immune Monitoring Shared Resource (Core B, directed
by Dr. Elaine Mardis with several subspecialy assistant directors). Core B provides integrated datasets via state-
of-the-art technologies including mass cytometry, single cell transcriptomics, and an array of other genomics
approaches that enable detailed characterizations and tracking of cancer cell immunogenicity, the tumor immune
microenvironment, and immunologic responses. We have also assembled strong external and internal scientific
advisory boards of renowned leaders whose expertise spans the projects and shared resources. The projects
are highly integrated and cross-informative. We propose that therapeutic regimens that combine modalities will
produce synergy that drives anti-tumor immune responses in preclinical pediatric cancer models, overcoming
the limitations of low mutational burdens. Our goal is to generate a sufficient body of knowledge with compelling
data to inform the rational design of future clinical trials and thereby improve the lives of children with cancer.
1
总体中心摘要
本申请描述了创建于2009年的儿科俄亥俄州-纽约约克癌症(Peds-ONC)免疫治疗中心。
对RFA的反应作为儿科免疫疗法发现和开发的第二个病灶
财团(PI-DDN)。为了补充PI-DDN资助的U 54(Maris和Mackall,MPI),
寻求利用适应性免疫来进一步开发针对新识别抗原的CAR-T细胞,我们提出
利用先天免疫来靶向儿科癌症,避免对常规治疗的抵抗,
进一步实现适应性/混合免疫方法。
我们的目标是(1)识别和克服利用NK和CAR-NK细胞作为癌症治疗的障碍,(2)
破坏对“自身”癌症相关蛋白的耐受性和(3)通过靶向抑制性免疫疗法增强免疫疗法。
骨髓细胞我们将通过四个项目来实现我们的目标,这些项目位于俄亥俄州的两个主要地点
(全国儿童医院)和纽约(纽约医学院),在哥伦布设有分中心(
俄亥俄州州立大学)和明尼阿波利斯(明尼苏达大学)。除了管理共享之外,
资源(核心A,由蒂莫西·克里普博士和副主任米切尔·开罗博士指导),这些项目是
由全面的基因组学和免疫监测共享资源(核心B,指导
由伊莱恩·马迪斯博士和几位助理导演执导)。核心B通过状态-
最先进的技术,包括大规模细胞计数,单细胞转录组学,以及一系列其他基因组学
这些方法能够详细表征和跟踪癌细胞免疫原性,肿瘤免疫原性,
微环境和免疫反应。我们还汇集了强大的外部和内部科学
由知名领导人组成的咨询委员会,他们的专业知识涵盖项目和共享资源。的项目
是高度整合和交叉信息的。我们建议,治疗方案,联合收割机的方式将
产生协同作用,在临床前儿科癌症模型中驱动抗肿瘤免疫应答,
低突变负荷的局限性。我们的目标是生成足够的知识体系,
这些数据将为未来临床试验的合理设计提供信息,从而改善癌症儿童的生活。
1
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
TIMOTHY P CRIPE其他文献
TIMOTHY P CRIPE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('TIMOTHY P CRIPE', 18)}}的其他基金
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
项目 4:利用溶髓病毒疗法靶向 M2 样巨噬细胞和 MDSC
- 批准号:
10885260 - 财政年份:2023
- 资助金额:
$ 25.37万 - 项目类别:
Oncolytic virus bispecific gene delivery for high grade gliomas
用于高级别神经胶质瘤的溶瘤病毒双特异性基因递送
- 批准号:
10832350 - 财政年份:2023
- 资助金额:
$ 25.37万 - 项目类别:
Project 4:Targeting M2-like Macrophages and MDSC with Myelolytic-Virotherapy
项目 4:利用溶髓病毒疗法靶向 M2 样巨噬细胞和 MDSC
- 批准号:
10885263 - 财政年份:2023
- 资助金额:
$ 25.37万 - 项目类别:
Training Program in Basic and Translational Pediatric Oncology Research
基础和转化儿科肿瘤学研究培训计划
- 批准号:
10408197 - 财政年份:2022
- 资助金额:
$ 25.37万 - 项目类别:
Overcoming Immunological Tumor Microenvironment Resistance in Ewing Sarcoma
克服尤文肉瘤的免疫肿瘤微环境耐药性
- 批准号:
10616121 - 财政年份:2022
- 资助金额:
$ 25.37万 - 项目类别:
Training Program in Basic and Translational Pediatric Oncology Research
基础和转化儿科肿瘤学研究培训计划
- 批准号:
10590705 - 财政年份:2022
- 资助金额:
$ 25.37万 - 项目类别:
IL1RAP CAR NK cells enhance targeting of Ewing Sarcoma (ES) alone and with combinatorial targeted immunotherapy
IL1RAP CAR NK 细胞单独或联合靶向免疫疗法可增强对尤文肉瘤 (ES) 的靶向作用
- 批准号:
10401167 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
相似海外基金
VLA-4–targeted 67Cu-LLP2A preconditioning enhances efficacy of T-cell-based adoptive immunotherapy
VLA-4™ 靶向 67Cu-LLP2A 预处理增强基于 T 细胞的过继免疫疗法的疗效
- 批准号:
10713034 - 财政年份:2023
- 资助金额:
$ 25.37万 - 项目类别:
Phase I first-in-human trial for ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
484371 - 财政年份:2023
- 资助金额:
$ 25.37万 - 项目类别:
Operating Grants
Phase I first-in-human trial of ThINKK adoptive immunotherapy in children with high-risk cancers
针对高危癌症儿童的ThINKK过继免疫疗法的I期首次人体试验
- 批准号:
473376 - 财政年份:2022
- 资助金额:
$ 25.37万 - 项目类别:
Operating Grants
Development of Adoptive Immunotherapy Focusing on Follicular Helper T Cell Biology
专注于滤泡辅助 T 细胞生物学的过继免疫疗法的发展
- 批准号:
21K16420 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10180117 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10364687 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Mathematical Model-Guided Adoptive Immunotherapy in Bladder Cancer
数学模型引导的膀胱癌过继免疫治疗
- 批准号:
10599851 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Elucidation of the function of the new NK cell subset and its application to adoptive immunotherapy
阐明新NK细胞亚群的功能及其在过继性免疫治疗中的应用
- 批准号:
21H04832 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Development of a combinatorial approach of antibody therapeutics and adoptive immunotherapy for cancer
开发抗体疗法和癌症过继免疫疗法的组合方法
- 批准号:
21K19422 - 财政年份:2021
- 资助金额:
$ 25.37万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Adoptive immunotherapy for adult T-cell leukemia/lymphoma with ex vivo expanded multi-tumor associated antigen specific cytotoxic T-cells
使用离体扩增的多肿瘤相关抗原特异性细胞毒性 T 细胞对成人 T 细胞白血病/淋巴瘤进行过继免疫治疗
- 批准号:
20K17375 - 财政年份:2020
- 资助金额:
$ 25.37万 - 项目类别:
Grant-in-Aid for Early-Career Scientists